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Abstract
The diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency is a crucial aspect in
the current phases of malaria control and elimination, which will require the wider use of 8-aminoquinolines
for both reducing Plasmodium falciparum transmission and achieving the radical cure of Plasmodium vivax.
8-aminoquinolines, such as primaquine, can induce severe haemolysis in G6PD-deficient individuals, potentially
creating significant morbidity and undermining confidence in 8-aminoquinoline prescription. On the other hand,
erring on the side of safety and excluding large numbers of people with unconfirmed G6PD deficiency from
treatment with 8-aminoquinolines will diminish the impact of these drugs. Estimating the remaining G6PD enzyme
activity is the most direct, accessible, and reliable assessment of the phenotype and remains the gold standard for
the diagnosis of patients who could be harmed by the administration of primaquine. Genotyping seems an
unambiguous technique, but its use is limited by cost and the large range of recognized G6PD genotypes. A
number of enzyme activity assays diagnose G6PD deficiency, but they require a cold chain, specialized equipment,
and laboratory skills. These assays are impractical for care delivery where most patients with malaria live.
Improvements to the diagnosis of G6PD deficiency are required for the broader and safer use of 8-aminoquinolines
to kill hypnozoites, while lower doses of primaquine may be safely used to kill gametocytes without testing. The
discussions and conclusions of a workshop conducted in Incheon, Korea in May 2012 to review key knowledge
gaps in G6PD deficiency are reported here.
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Background
The 8-aminoquinolines, a class of drugs discovered almost
80 years ago, remains unique among anti-malarial drugs
in having activity against the sexual stages (gametocytes)
of P. falciparum and dormant stages of Plasmodium vivax
(hypnozoites). Despite being an intrinsic part of most
national and international malaria treatment guidelines,
the use of primaquine in the treatment of P. vivax as well
as P. falciparum is often deferred by attending physicians
and healthcare providers. Lingering uncertainty regarding
the efficacy and tolerability of primaquine is the most
likely reason for this under-utilization. Yet the unique fea-
tures of primaquine could be critical to tackle three of the
most important challenges to malaria therapeutics: 1) The
interruption of malaria transmission: despite massive gains
made in reducing the burden of malaria in Asia as well as
Africa, interruption of the residual transmission has been
challenging. Expanding the use of primaquine has been
proposed to reduce the transmission potential in both
symptomatic patients and asymptomatic parasitaemia. A
World Health Organization (WHO) expert committee
came to the conclusion that primaquine can be safely used
as a single dose (0.25 mg base/kg) even in individuals with
G6PD deficiency [1]. Evidence including series of studies
from China suggests that such a single low-dose prima-
quine may be sufficient to kill gametocytes [2,3]. 2) Redu-
cing the spread of artemisinin resistant P. falciparum
strains: one of the greatest threats to current treatment
strategies is the emergence and spread of P. falciparum
strains resistant to artemisinin derivatives [1-3]. Artemisi-
nin resistance was first reported in Western Cambodia
and has been documented on the western border of
Thailand by 2012 [4-6]. Several approaches using game-
tocytocidal drugs to interrupt malaria transmission and ul-
timately eliminate malaria have been proposed. In order of
increasing complexity these interventions include adding
gametocytocidal drugs as part of case management,
screening followed by treatment of cases, and mass drug
administrations. 3) The radical cure of P. vivax: although
current malaria control efforts have been successful in re-
ducing the transmission of falciparum malaria they have
had a more limited effect on the transmission of vivax
malaria, resulting in a relative increase of the proportion
of malaria cases due to P. vivax in areas where effective
malaria control programmes have been implemented [7].
This reflects the different transmission dynamics of P.
vivax infections and the difficulties in eliminating the dor-
mant liver stages. To address this problem malaria con-
trol programmes need to be able to deploy effective
radical cure of P. vivax, to kill both erythrocytic and
exo-erythrocytic stages of the parasite. The only drugs
currently available with activity against all stages of P.
falciparum gametocytes as well as P. vivax hypnozoites
are the 8-aminoquinoline drugs, of which only
primaquine and the prodrug bulaquine are currently li-
censed. Bulaquine is produced by Central Drug Re-
search Institute (CDRI), Lucknow and licensed in India
only [8,9]. A long-acting 8-aminoquinoline, tafenoquine,
has been in development for nearly 30 years and could
be licensed in years to come.
Despite the therapeutic advantages of the 8-amino-
quinolines, the wider use of drugs such as primaquine
is restricted by their toxicity profile. The most import-
ant adverse effect of 8-aminoquinolines is dose-related
haemolysis. In people with an inherited deficiency of
glucose-6-phosphate dehydrogenase (G6PD) a single
dose of primaquine can trigger a severe haemolysis
reaction. The first report of 8-aminoquinolines-related
haemolysis was recorded in 1926 following the
administration of pamaquine, the earliest available
8-aminoquinoline, also known as plasmoquine or
plasmochin: “On the fourth day of treatment, after the
fever had disappeared the patient developed profound an-
aemia, leucocytosis, jaundice, nausea, vomiting, and som-
nolence. He died within 48 hours of the onset of this
sudden attack. The toxic influence of plasmochin com-
pound was suspected to have played an important role in
the cause of death” [10]. It took until the 1950s for re-
searchers to discover variations in G6PD which confer a
risk for haemolysis following the administration of prima-
quine [11,12]. The precise mechanism of haemolysis re-
mains unknown. G6PD catalyses the rate-limiting reaction
of the hexose monophosphate shunt, the primary source
of electrons to reduce nicotinamide adenine dinucleotide
phosphate (NADP+). NADPH is key to maintaining the
redox equilibrium within erythrocytes (red blood cells,
RBC). It has been proposed that an oxidized metabolite
of primaquine may precipitate the molecular events
leading to haemolysis. The appearance of Heinz bo-
dies, potentially derived from haem moieties dislodged
from their hydrophobic globin folds, signal the onset
of haemolysis.
Haemolysis in individuals with G6PD deficiency has
been reported to follow therapy with a range of anti-
malarial drugs (8-aminoquinolines, including primaquine,
tafenoquine and pamaquine), sulphones (dapsone),
sulphonamides (such as sulphanilamide, sulphameth-
oxazole, and mafenide), analgesics (such as aspirin,
phenazopyridine, and acetanilide), non-sulpha antibiotics
(nalidixic acid, nitrofurantoin, isoniazid, and furazolidone),
methylene blue and naphthalene [13]. In addition, haem-
olysis can also be induced by foods (such as fava beans),
henna, and infections (including Hepatitis viruses A or B,
cytomegalovirus, pneumonia, and typhoid fever) [13,14].
Keeping in mind that the clinical evidence linking some of
the compounds with haemolysis in G6PD-deficient people
is weak, there may be no causal relationship between the
compound and the less frequent reactions.
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Following administration of a standard 14-day course of
primaquine (0.25 mg/kg body weight per day) the majority
of treated people experience some degree of subclinical
haemolysis regardless of G6PD status [15]. The clinical
significance of a haemolytic episode can range from mild
and self-limiting to severe and life threatening, depending
upon the exposure to the drug, the specific variant of
G6PD deficiency and incompletely understood host fac-
tors. Unfortunately, primaquine sensitivity among the
many G6PD variants has only been characterized reliably
for two variants, Mediterranean and Mahidol. These vari-
ants represent severe and moderate degrees of sensitivity
to primaquine respectively. African A-, frequently consid-
ered a variant associated with mild disease, can also result
in more severe illness following primaquine administra-
tion [16,17]. Therefore, the risk of serious harm in any
given population exposed to primaquine therapy remains
largely unknown. There is a possibility that other variants
of extreme sensitivity to primaquine, similar to the Medi-
terranean variant, also exist, but are as yet undescribed. A
small fraction of people receiving primaquine will hae-
molyse sufficiently to have clinical signs, including clinical
anaemia, bilirubinaemia resulting in jaundice, and darkly
coloured urine. Severe haemolysis can lead to serious
clinical consequences including renal failure and haemo-
dynamic compromise [18]. Potentially life-saving proce-
dures such as blood transfusions and renal dialysis are
expensive, carry a risk of adverse events on their own, and
are often not readily available in poorly resourced commu-
nities at high risk for malaria.
There is little if any information on the safety of prima-
quine use during pregnancy. Since the unborn child is not
accessible to testing there is a risk of exposing a G6PD
deficient child to primaquine which at least in theory
could result in hydrops fetalis. Women who perceive
themselves at risk of being pregnant should not be treated
with primaquine. There is a need for pharmacovigilance
when primaquine is used in populations which could
include pregnant women [19].
The incidence of severe adverse reactions secondary to
primaquine administration is difficult to determine since
most reports do not provide certainty regarding the nu-
merators or the denominators involved. A major review of
the safety data related to primaquine and its predecessors
plasmoquine or plasmochin archived by the WHO and
the League of Nations detected 13 deaths associated the
administration of primaquine. Acknowledging the meth-
odological limitations in estimating the denominator the
investigators calculated “the risk of death associated with
primaquine ingestion at approximately 1 in 692,307” [20].
The risk of severe adverse events was related to the total
dose of primaquine and the age of the patient. The investi-
gators estimated that the risk of severe haemolysis in mass
administrations of primaquine was 1.8 per million.
Uncertain about the potential risks of primaquine
administration, policymakers and practitioners are often
reluctant to put patients at risk of the potential conse-
quences of primaquine toxicity. Few patients will blame
their healthcare provider for a malaria relapse months
after treatment in contrast to an episode of severe
haemolysis immediately following the start of treatment.
From the practitioner’s perspective it may appear ad-
vantageous to withhold primaquine therapy, particularly
if patients are not requesting it.
Primaquine toxicity in patients with G6PD deficiency is
a significant barrier to the effective delivery of therapies
essential to combating the endemic malarias. A more
satisfactory approach to the detection and management of
malaria patients with G6PD deficiency would unlock a
much broader anti-malarial armamentarium. This review
discusses the key gaps in understanding the G6PD defi-
ciency problem and provides strategies for its detection
and management.
Genetics of G6PD deficiency
The gene encoding the G6PD enzyme is located at the
q28 locus on the X-chromosome. As a result, the pheno-
type due to genetic mutations is more likely to be manifest
in males. Heterozygous females display varying levels of
enzyme deficiency due to the partial inactivation of one
female X chromosome a phenomenon first described by
Mary Lyon in 1961 and hence known as lyonisation [21].
Homozygous deficient females are rare due to the relative
improbability of such inheritance. The WHO groups
G6PD genetic variants somewhat arbitrarily into five clas-
ses based on levels of enzyme activity. According to this
WHO classification thresholds of 10 and 60% are used to
define the degree of G6PD activity [22].
I. Severe deficiency (<10% activity) with chronic
(non-spherocytic) haemolytic anaemia;
II. Severe deficiency (<10% activity), with intermittent
haemolysis;
III. Mild deficiency (10-60% activity), haemolysis with
stressors only;
IV. Non-deficient variant (60 - 100% activity), no
clinical sequelae;
V. Increased enzyme activity (>100% activity), no
clinical sequelae.
With the exception of rare sporadic WHO class I indi-
viduals, most G6PD-deficient individuals are asymptom-
atic. One hundred and eighty-six genetic determinants of
G6PD deficiency have been described, including point
mutations, deletions, and insertions [14,23]. Different
polymorphisms result in a spectrum of enzyme deficien-
cies ranging from no, mild to severe effects. The combin-
ation of allelic variations at positions 202 and 376 of the
von Seidlein et al. Malaria Journal 2013, 12:112 Page 3 of 12
http://www.malariajournal.com/content/12/1/112
G6PD gene has been investigated extensively in sub-
Saharan Africa [24]. Relative to the wild-type G6PD B
haplotype (202G/376A), the A haplotype (202A/376A)
results in 85% enzyme activity, whilst the A haplotype
(202A/376G) results in a more severe phenotype with just
12% of mean enzyme activity [25]. In most regions with
high G6PD prevalence several polymorphic alleles are in
circulation with the notable exception of sub-Saharan
Africa where A is thought to cause 90% or more of G6PD
deficiency [14]. Other relatively common polymorphi-
sms, e.g., G6PD-Mediterranean, G6PD-Canton, or G6PD-
Mahidol are associated with class II or class III deficien-
cies in the WHO classification. Considering the overall
paucity of data, more recent reports question the rele-
vance of the classification especially for policymakers [16].
The geographic distribution of G6PD deficiency
It has been estimated that more than 400 million people
worldwide are affected by G6PD deficiency [14]. Individ-
uals with G6PD deficiency have an evolutionary survival
advantage in malaria-endemic regions as G6PD deficiency
confers a degree of protection against severe malaria
[26,27]. The selective advantage of G6PD deficiency under
malaria pressure has left its mark in the human genome as
a “selective sweep” surrounding the G6PD gene [28,29].
Not surprisingly G6PD deficiency is most prevalent in
regions where malaria is or was prevalent (Figure 1).
Howes and co-workers have identified 1,734 commu-
nity G6PD surveys globally of which 1,289 (74%) were
conducted in malaria-endemic countries and used this
evidence-base to model a continuous prevalence map of
the deficiency [30]. The prevalence of G6PD deficiency
was lowest or absent in the Americas, and highest in
sub-Saharan Africa. The region with the single highest
predicted prevalence was in the eastern province of
Saudi Arabia. The prevalence of G6PD deficiency
tended to be lower, but heterogeneous across central
and Southeast Asia, with “hotspots” identified in eastern
India, at the Thai-Lao border and in the Solomon
Islands. Despite the very large number of studies under
review there remains uncertainty regarding the geo-
graphic distribution of G6PD deficiency prevalence in
many areas. Uncertainty metrics accompanying the
modelled map allow prioritization of areas where add-
itional community surveys are needed. Furthermore, the
prevalence of the deficiency is far from homogeneous,
with considerable variations even within countries,
further emphasizing the need for additional data. An
acknowledged limitation of the currently available in-
formation is the variability in G6PD deficiency tests
used. It is difficult to extrapolate from the reported
prevalence of G6PD deficiency to the risk of severe
primaquine-induced haemolysis. The modelled preva-
lence maps are supplemented with data on genetic vari-
ants, which allows a better prediction of the risk of
haemolysis. The maps will hopefully help policymakers
to optimize safer strategies to deploy primaquine.
Tests to detect G6PD deficiency
The available tests to assess an individual’s G6PD activity
status can be broadly divided into genetic and phenotypic/
biochemical approaches (see Table 1).
DNA-based genotyping
DNA-based genotyping and targeted re-sequencing efforts
have identified a range of variants associated with G6PD
deficiency worldwide, including regional variants. These
approaches, whilst currently not practical for point-of-care
use, may facilitate large-scale screening efforts with poten-
tially quantitative measures of deficiency. Not all G6PD
Figure 1 The world map [30] of G6PD alleles associated with enzyme deficiency.
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variants necessarily underlie deficiency and, thus, the
clinical relevance of variants needs to be assessed with
phenotypic correlates of enzyme activity and the potential
for 8-aminoquinoline induced haemolysis. The size
(~16.2 Kb) and complexity of the G6PD gene makes com-
prehensive re-sequencing challenging. However, new
high-throughput genotyping platforms enable rapid and
cost-effective screening of predefined variants in hundreds
of individuals [49]. Genotyping known polymorphisms is
conceptually attractive because it provides an unequivocal
answer whether a particular polymorphism is present or
not. However, unknown variants, and complex haplotypic
determinants may be missed. Although specificity is high,
the sensitivity of genotyping approaches to detect popula-
tions at risk will vary according to the panel of genetic
variants and their local prevalence. In Burkina Faso where
the G6PD-A haplotype encompasses more than 90% of
mutations, a genotyping assay has been successfully
Table 1 Summary phenotypic tests
Description Setting required Reference
Direct tests
Spectrophotometry Quantitative gross enzymatic activity assay. The initial reaction
velocity of the G6PD reaction is measured
spectrophotometrically as an increase in absorbance at
340 nm. Despite standardized methods variations in results
have been observed between sites.
Requires a biochemistry laboratory and may vary
with ambient temperature and humidity.
[31-34]
”Beutler’s” fluorescent
spot test
A popular screening test in which a drop of blood incubated
with G6PD reaction substrates is placed on filter paper and
illuminated with UV light, the presence or absence of
fluorescence provides a categorical measure of G6PD activity.
Recommended as the most suitable method for
screening in the field, despite the need for an
UV lamp, water bath incubator, and
micropipette [34].
[35]
Indirect tests
Methaemoglobin
reduction test (MRT)
G6PD activity is assessed by first treating RBCs with nitrite and
then examining the rate of NADPH-dependent
methaemoglobin reduction in the presence of an appropriate
redox catalyst and substrate (glucose).
Requires a biochemistry laboratory. [36,37]
Brilliant cresyl blue,
resazurin, or
formazan ring tests
Indirect assays of G6PD activity translate NADPH production
into a colorimetric readout using chromophores. It takes
several hours to process these assays.
Requires a biochemistry laboratory. [35,38-41]
Cytochemical typing
Methaemoglobin
elution test
RBCs are labelled according to their relative methaemoglobin
content based on MRT.
Requires a biochemistry laboratory. [42]
Cytofluorometric
assay
Quenching of glutaraldehyde-induced autofluorescence by
formazan is detected by cytofluometry. Cytofluorometric
assays can provide valuable data based on individual cells,
which neither genotyping nor biochemical assays can provide
but require considerable resources.
Requires a laboratory with experience in
cytofluometry.
[43,44]
Rapid tests
Hirono – 1-methoxy
PMS Sephadex
method
Substrate mixture (G6P, NADP, saponine) and MTT-PMS
mixture are dissolved in water and mixed with Sephadex gel.
Requires a biochemistry laboratory and requires
a skilled technician.
[45]
WST8/1-methoxy
PMS method
An enzymatic method which utilizes a tetrazolium salt WST8,
and a PMS hydrogen carrier, 1-methoxy PMS.
The quantitative, colorimetric nature, the
reduced light sensitivity and the possibility of
using this method with dried bloodspots make
it more suitable for field use than the Hirono
method.
[38,46]
Rapid, point-of-care tests
BinaxNowW G6PD
test
A qualitative enzyme chromatographic test distinguishes
accurately between samples with G6PD activity less than 4.0
U/g of haemoglobin and those with greater enzyme activity.
Approved by the United States Federal Drug Administration
and rather costly. Requires an operating temperature 18° to
25°C, a cold chain for reagents and pipettes. Sensitivity 98%,
Specificity 98%.
Specifically developed as a point of care test. [47]
CareStartW G6PD
deficiency screening
test
A qualitative enzyme chromatographic test, distinguishes
between samples with G6PD activity less than 2.7 U/g of
haemoglobin and those with greater enzyme activity. In
development, not yet commercially available. Sensitivity 68%,
Specificity 100%.
Is being developed as a point of care test and
may become useful as a public health tool.
[46,48]
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employed with sensitivity and specificity comparable to a
phenotypic assay [50]. A more recent multicentre study
conducted in Burkina Faso, Ghana, Kenya, Nigeria,
Tanzania, Mali found the correlation between genotype
and phenotype was in contrast rather disappointing.
Phenotype test specificity in detecting hemizygous males
was 71% (70/99) and 48% (12/25) for homozygous females
[51]. Heterozygous females displayed a wide range of
G6PD activity. Furthermore information regarding the
correlation between genotyping results and clinical out-
comes is very limited. The screening for single nuclear
polymorphisms can be challenging in malaria endemic set-
tings with limited resources. Screening for multiple poly-
morphisms and analysing the data is feasible in research
settings but becomes increasingly complex. The difficulties
of performing and analysing such tests in a field setting
not to mention the costs are a major obstacle for the wide-
spread use of such molecular diagnostics in field settings.
Phenotypic testing
Phenotypic testing of the enzymatic activity of G6PD on
freshly collected venous blood remains the most widely
used diagnostic method and the most informative indica-
tor of the level of enzyme function [46]. There are more
than 30 G6PD phenotype deficiency-testing products
currently on the market, including both quantitative and
qualitative methods, however rigorous data evaluating the
tests are limited. Most available assays have not been
evaluated in malaria-endemic settings. Currently only
two tests may be appropriate for point-of-care use:
BinaxNowW and CareStartW. Phenotypic tests can be
divided into four broad categories which are summarised
in Table 1:
a) Direct tests measure the enzymatic activity of
G6PD. The standard measurement of such
enzymatic activity remains spectrophotometry [31].
The basic assay of the enzyme haemolysate was first
described in 1952 [32]. Commercial test kits have
simplified the assays [33], but they still require a
biochemistry laboratory and a skilled technician.”
Beutler’s” fluorescent spot test is a popular screening
test in which haemolysate is incubated with G6PD
reaction substrates is placed on filter paper and
illuminated with UV light (450 nm) [34]. The
presence or absence of fluorescence provides a
categorical measure of G6PD activity. The
fluorescent spot test is currently recommended as
the most suitable method for screening in the field
even though it is far from ideal [34]. Besides
requiring an UV lamp, water-bath incubator, and
micropipettor especially in field settings it can be
difficult to decide whether or not fluorescence is
present. Even under ideal conditions, intermediate
enzyme activity may be difficult to appropriately
classify as deficient or normal (Figure 2).
b) Indirect phenotypic tests include the
methaemoglobin reduction test (MRT) [36]. After
treating RBCs with nitrite and a glucose substrate,
the MRT measures the rate of NADPH-dependent
methaemoglobin reduction in the presence of an
appropriate redox catalyst. The rate of NADPH-
dependent methaemoglobin reduction correlates
with G6PD activity. Other indirect assays of G6PD
activity use chromophores, such as brilliant cresyl
blue, resazurin, formazan to monitor NADPH
production. These tests produce a colorimetric
readout.
c) Cytochemical assays assess the G6PD status of
individual erythrocytes and hence can be used to
detect hemizygous-deficient males, homozygous-
deficient females, and heterozygous-deficient females
[52]. Cytochemical typing methods include the older
methaemoglobin elution test in which RBCs are
labelled according to their relative methaemoglobin
content based on the indirect MRT described above.
More recently developed cytofluorometric assays
detect the quenching of glutaraldehyde-induced
autofluorescence by formazan using flow cytometry
[43,44]. Cytofluorometric assays can provide
valuable data based on individual cells which neither
genotyping nor biochemical assays can provide. In
practice such methods are limited by the need for
extensive laboratory capacity including expensive
equipment and skilled staff. These tests are useful in
Figure 2 An example of “Beutler’s” fluorescent spot test.
Samples with enzyme activity are fluorescent while samples with
reduced enzyme activity produce no fluorescence.
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well-equipped laboratories, but are of limited use in
field settings.
d) Rapid, point-of-care tests allow healthcare providers
to diagnose G6PD deficiency in the clinical setting
and could influence the case management of vivax
malaria. Several tests have been developed; the more
recent products approach the ease of the
chromatographic malaria tests, which have
revolutionized the diagnosis of malaria.
The Hirono–1-methoxy PMS Sephadex method re-
quires a substrate mixture (G6P, NADP, saponine) and a
mixture of the tetrazolium salt MTT with the phenazine
methosulfate (PMS) which are dissolved in water and
mixed in a Sephadex gel [45]. While this method has
been used in the field the level of sophistication
required to process this assay is far from trivial. The
WST-8/1-methoxy PMS method (DojindoW, Japan) is an
improvement on Hirono’s method. This is an enzymatic
method which utilizes a tetrazolium salt WST8 and a
PMS hydrogen carrier, 1-methoxy PMS [38]. Specifically,
the reduced light sensitivity, quantitative, colorimetric
nature, and the capacity for use on dried bloodspots make
this method more suitable for field use than the Hirono
method.
Currently two chromatographic test are licensed and
commercially available: BinaxNowW G6PD test and Care-
StartW G6PD deficiency screening test, the latter intro-
duced more recently. The BinaxNowW G6PD deficiency
screening test is a qualitative enzyme chromatographic
test which in a laboratory setting distinguished accurately
between samples with G6PD activity less than 4.0 U/g of
haemoglobin and those with greater enzyme activity [47].
The test needs to be performed between 18°C and 25°C,
requires venous blood, a cold chain for the reagents and
pipettes, which are a major operational limitation in many
settings. The test has been cleared for distribution by the
FDA and is used by the US military, but pricing (estimated
around USD $25/test) may be prohibitive for natio-
nal malaria programmes. The CareStartW G6PD deficiency
screening test is a qualitative enzyme chromatographic
test based on the reduction of light yellowish tetrazolium
dye to purple-coloured formazan. The version of the
test used in published studies aims to distinguish
samples with G6PD activity less than 2.7 U/g of haemo-
globin from those with greater enzyme activity [48].
The CareStartW G6PD deficiency screening test is con-
sidered promising but, like the BinaxNow product, the
currently commercially released version of the test
needs to be optimized and validated for use in field
settings. Upgrades of the CareStartW G6PD deficiency
screening test are in development including a version
which allows quantitative estimate of G6PD activity
using a reader.
These biochemical approaches offer a functional analysis
of G6PD deficiency, but are often difficult to interpret,
especially for mosaic female heterozygotes, who may also
haemolyse following treatment with 8-aminoquinolines.
The interpretation of results of these tests should further
take into account the duration of malaria infection, an-
aemia of the patient and other haematologic parameters.
It is possible that an acute febrile episode drives haemoly-
sis. Measured G6PD levels may be reduced during acute
malaria episodes. Serial evaluations of G6PD activity
during the acute malaria episode and following recovery
are on-going in Thailand (see below) and will help define
the dynamics of this process. A major challenge for these
tests is to ensure their sensitivity in detecting vulnerable
populations, choosing an appropriate cut-off value for
deficiency and ensuring affordable scale-up in field set-
tings. Neither genetic nor gross biochemical approaches
capture the full picture of G6PD activity and hence a com-
bination of assays may be needed for a more complete
understanding of G6PD deficiency. Treatment decisions
in contrast may be based on rapid diagnostic tests, which
are currently in development and will be of critical
importance for the safe deployment of primaquine and
other 8-aminoquinoline anti-malarials.
Experiences and perspectives in several Asian Pacific
countries on tests to diagnose G6PD deficiency
Testing along the Thai-Burmese border around Mae Sot
showed a prevalence of G6PD phenotypic deficiency
between 9% and 18% among healthy men of Karen and
Burmese ethnicity, using the fluorescent spot test
[18,30]. Approximately 90% of deficient subjects identi-
fied were of the G6PDd-Mahidol genotype [30]. As part
of on-going studies to determine the relationship
between G6PD genotype and the risk for primaquine-
induced haemolysis, a panel of mutations other than the
G6PD-Mahidol genotype will be sequenced. Diagnosing
of G6PD deficiency in women using rapid tests carries
more uncertainty than in men. This observation com-
bined with the potential dangers of using primaquine in
pregnancy could have implications for the population
coverage if primaquine mass administrations are to be
safely deployed. A better understanding of the risk of
haemolysis may be gained through quantitative assess-
ment of G6PD activity using spectrophotometric and
cytochemical assays.
Pailin, Cambodia is considered an epicentre of the
emergence of multidrug resistant P. falciparum and as
such a crucial location for deploying primaquine safely
as part of strategies aimed at containing resistant para-
sites [4,53,54]. Primaquine has been used in Cambodia
in the past as part of malaria control efforts. There are
anecdotal reports of blackwater fever and some deaths.
In addition, children presented to one paediatric referral
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hospital with blackwater fever following the ingestion of
traditional medicines, sulphonamides and anti-malarial
drugs [55]. Mass treatment has been used in Cambodia,
which included a 9 mg dose of primaquine [56].
Although there were no reports of blackwater fever
there was no active surveillance for haemolysis or other
adverse events. A programme of mass treatment with
primaquine in the 1980s (in which the dose of prima-
quine was not specified) is thought to have resulted in
cases of severe and fatal haemolysis, precipitating the
complete abandonment of the drug in malaria control.
The prevalence of G6PD deficiency in Cambodia is esti-
mated to be between 13% and 26% among males and 3%
to 4% among females using diagnostic tests which could
have missed heterozygous females [57-59]. The most
frequently encountered genotypes are G6PD Viangchan
followed by Mahidol, Union, and Coimbra. Recent
research conducted in Pailin, in the north-western part
of the country, suggests a 15% prevalence of G6PD defi-
ciency among males and 7% among females [48].
According to the WHO classification, 1% of those tested
were in class I, 6% in class II and 11% in class III. In
95% of the individuals tested the genotype was G6PD-
Viangchan. Experience with the florescent spot test in
Cambodia suggests that the test fails to detect reliably
heterozygous females. A recent systematic evaluation of
the CareStartW G6PD test in this region, suggests a role
for this test in the region [48].
In the Philippines routine screening of newborns for
G6PD deficiency using direct tests is part of the national
newborn screening programme. Espino and co-workers
recently evaluated two assays in Puerto Princesa City,
Palawan. The direct fluorescent spot test was compared to
the rapid colorimetric test WST-8 in their ability to detect
G6PD deficiency in 537 high school students. The investi-
gators found that both assays were difficult to implement
in field conditions and were unsuitable for screening in
the Philippines. In addition the investigators found dis-
crepancies between test results based on venous compared
to capillary blood. The discrepancies may be due to higher
haemoglobin levels in capillary blood.
A range of surveys in the Indonesia suggests a preva-
lence of genotypic G6PD deficiency between 0.6% and
14% [38,45,60-70]. The prevalence of genotypes respon-
sible for G6PD deficiency in Indonesia is highly heteroge-
neous with at least 12 documented G6PD polymorphisms,
including Gaohe (95 A > G), Vanua Lava (383 T > C),
Mahidol (487 G > A), Mediterranean (563 C > T), Coimbra
(592 C > T), Bajo Maumere (844 G > T), Viangchan
(871 G > A), Chatham (1,003 G > A), Chinese–5
(1,024 C > T), Surabaya (1,291 G > A), Canton (1,376 C > G),
and Kaiping (1,388 G > A). On-going research on Sumba
Island by Satyagraha and co-workers found a prevalence
of G6PD deficiency ranging between 3.0% and 6.6% in
three districts. The overall prevalence of G6PD deficiency
in Sumba (Southwest, West and Central) was 4.9%. These
prevalence rates mirror the prevailing pattern of malaria
endemicity. Preliminary findings suggest a relatively low
sensitivity of the CareStartW G6PD deficiency screening
test in the field setting in Sumba. Possible explanations
include the high humidity, high temperature, and an
unstable supply of electricity, all of which rendered the
quantitative G6PD gold standard subject to likely error.
Relatively little is known regarding G6PD deficiency in
the Solomon Islands [71]. The WST8/1-methoxy PMS
method was successfully used by Kuwahata and co-
workers as part of a large survey in the Solomon Islands
[46] in which 8,541 people from 41 villages were screened
in the Isabel province. The prevalence of G6PD deficiency,
defined by enzyme activity <30% relative to a wild-type
control, was 20% with 7% of individuals classified as
having of severe G6PD deficiency (WHO class I-II). The
applicability of a filter-paper, mass-screening assay based
on the WST8/1-methoxy PMS method to provide preva-
lence of G6PD deficiency in Isabel Province was evaluated.
This study showed that it was possible to undertake large-
scale mass screening of G6PD deficiency in the field using
the filter-paper assay in order to assess prevalence of the
deficiency. The filter-paper method showed complete con-
cordance with biochemical testing. Although these studies
demonstrated utility of the test, reliability of G6PD
measurements was limited by high humidity and a lack of
correction for the storage period.
Economic perspectives on G6PD testing
There is a growing awareness that robust and reliable
G6PD tests that can be used in remote, malaria-endemic
regions are needed. The primary demand for G6PD tests
comes from malaria control programmes in vivax-
endemic countries, where prolonged and higher doses of
primaquine are required for radical cure. A single low-
dose primaquine (0.25 mg base/kg) can be safely adminis-
tered even in individuals with G6PD deficiency and is
sufficient to kill gametocytes as mentioned earlier [2,3].
Besides the malaria control programmes, the pharma-
ceutical industry is interested in reliable, affordable point-
of-care tests for G6PDd to license and safely roll-out new
8-aminoquinolines. Tafenoquine, the putative successor of
primaquine, has been in development for over three de-
cades [72]. Being another 8-aminoquinoline, the potential
of tafenoquine to trigger haemolysis in G6PD-deficient
people has been the major focus of early Phase I and II
studies. Safe deployment of novel 8-aminoquinolines, such
as tafenoquine, for the radical cure of vivax malaria will
require use of a rapid diagnostic test prior to the adminis-
tration of the drug in an individual who has not been
tested previously. If a specific G6PDd test were to be co-
developed as a “companion diagnostic” it would require
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approval from the relevant regulatory agencies for use
with that drug. Alternatively, assuring the availability of a
test prior to prescription of the drug without massive
waste of unused tests is a complex task. For example, if
the diagnostic is supplied separately of the drug physicians
will depend on continuous supply of this diagnostic test,
requiring a secure but separate supply chain. Since prima-
quine is currently prescribed without prior testing, intro-
ducing a test will have to change physician behaviour.
Adding a diagnostic test will also increase the cost of the
radical cure of vivax malaria.
Equally important for the development and regulatory
approval of rapid diagnostic tests to prevent haemolysis
may well be the unresolved question of which level of
enzyme activity carries an unacceptable risk for severe
haemolysis. The absence of a consensus over what repre-
sents an unacceptable level of haemolysis is not only the
major challenge for the development of tests to diagnose
G6PD deficiency but also a critical barrier to the regula-
tory approval of candidate 8-aminoquinolines.
Several institutions and companies are currently in-
volved in developing new generation G6PD testing kits.
The Program for Appropriate Technology in Health
(PATH), an international, non-profit global health orga-
nization, has identified the development of diagnostic tests
to detect G6PD deficiency as an urgent priority. Other
institutions include the Foundation for Innovative Diag-
nostics (FIND) as well as the UK Department for Inter-
national Development (DFID) and the Bill and Melinda
Gates Foundation (BMGF) have indicated interest in
supporting the development of diagnostics to detect
G6PD deficiency.
A first step toward the development of a robust clinical
test is the description of a target product profile (TPP) of
the end product (Table 2). Major challenges identified
already include the dependence of G6PD activity on envir-
onmental temperature and humidity. Test results should
be adjusted by a temperature and perhaps a humidity
correction factor. Secondly the correct read-out of reac-
tion rates may be time sensitive. Hence a handheld reader
of G6PD tests which could also adjust for environmental
temperature may be required to provide accurate and
reproducible test results.
The broader benefits of G6PD testing
The broader benefits of a reliable point-of-care test are
likely to be considerable, but benefits to individuals and
to society need to be weighed against the potential costs
and risks of the overall objective. Such an analysis
should consider the alternatives to the introduction of
testing, including the status quo (in most cases no
primaquine and no testing), as well as the introduction
of different primaquine treatment regimens without
prior G6PD testing. For the latter, the potential benefits
of testing in terms of decreased risk of primaquine-
induced haemolysis needs to be balanced against the
cost of diagnosis and the potential negative conse-
quences of introducing the tests, including those due to
poor test accuracy. The potential impact of rolling out
primaquine on endemic parasite populations has not
been measured, but may be rationally presumed to be
very significant given its broad therapeutic range. Reli-
able, accurate, affordable and easy to use G6PD testing
may dramatically improve primaquine therapy by per-
mitting relatively high dose and short duration regimens
rather than the current standard regimen of 14 days’
duration. Ultimately, at the societal level the accumu-
lated costs and consequences of continued malaria
transmission, morbidity and mortality need be consid-
ered in a global economic analysis.
Conclusions, research priorities and an action plan
The exploration of safe but efficacious doses of 8-
aminoquinolines for the radical cure of vivax malaria and
Table 2 An outline for a possible TPP for a rapid test to detect G6PD deficiency used prior to the treatment of vivax
malaria
Feature Ideal specification Comments
Output Level of G6PD deficiency In the absence of a consensus a quantitative read out may be
most appropriate. In the absence of a consensus a qualitative
read out may be controversial.
Use case On patients with confirmed malaria infection. This is an additional cost to malaria case management.
User Someone who performs malaria RDTs or microscopy. A quantitative read-out could come from a reader or scanner.
Sensitivity and
Specificity
Must accurately classify all patients with G6PD levels below a pre-
defined cut-off. No patients with potentially dangerously low
G6PD levels should be misclassified as normal.
It is unclear on what the suitable cut-off should be. Too low and
the risk of haemolysis increases. Too high primaquine is denied
to more patients who need it.
Environmental
tolerance
25-38°C, 40-90% humidity Enzyme activity is extremely temperature sensitive.
Result read
window
< 20 minutes Technically challenging for an enzyme reaction.
Specimen type Finger stick Currently very limited data with finger stick specimens.
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the reduction of falciparum transmission has a high pri-
ority in global malaria research (see also Table 3 below).
The most relevant phenotype regarding potential prima-
quine sensitivity is residual G6PD enzyme activity but
the evidence that informs any correlation between
G6PD and primaquine sensitivity phenotypes remains
crude. The first step towards a better understanding is
the collection of data on the reduction in enzyme activ-
ity that results in a significant risk of haemolysis follow-
ing administration of a standard regimen of an
8-aminoquinoline. A major challenge for G6PD testing
is heterozygous females. Lyonization of the trait renders
expression of the mutant gene anywhere between 0%
and 100% and is a random event. This can result in
unrecognized heterozygous females being at risk for
haemolysis. This problem requires careful study, apply-
ing cytochemical characterization of the erythrocyte
populations of girls and women. There is no consensus
on what level of enzymatic activity is required to com-
pletely exclude severe haemolysis. The current WHO
classification suggests a rather arbitrary cut-off of less
than 10% of enzyme activity is indicative of a significant
risk of severe haemolysis. Neither is there agreement on
what constitutes a clinically significant fall in a patient’s
haemoglobin concentration. To understand the fraction of
the drop in haemoglobin attributable to 8-aminoquinoline
therapy it would be critical to understand the level of
haemolysis attributable to uncomplicated malaria with-
out 8-aminoquinoline treatment. For a broader under-
standing between the genotype, the phenotype, the
threshold for haemolysis and what represents an
unacceptable risk, clinical observations need to be
combined with sequence-based analysis of the G6PD
gene, cytofluometric assay and candidate diagnostic
tests.
The uncertainties regarding the regional distribution of
G6PD genotypes suggest a need for phenotypic and geno-
typic surveys in areas with sparse or outdated data as
well as correlates with haemolysis phenotypes. It is
not sufficient to conduct such surveillance in selec-
ted, established study centres. Specifically, understudied
malaria-endemic regions require collection of high-quality
data on G6PD deficiency. Current plans to conduct
multicentre studies of 8-aminiquinolines could serve as a
platform for the in-depth evaluation of G6PD diagnostic
kits.
The 8-aminoquinoline doses required to kill the meta-
bolically inactive hypnozoites for the radical cure of vivax
malaria are multi-fold higher than doses required to kill
gametocytes for the interruption of falciparum malaria
transmission [2]. A series of studies conducted in China
suggests that low doses of primaquine (0.25 mg base/kg)
kill all stages of P.falciparum gametocytes [3]. Expert opin-
ions suggest that such a single, low-dose primaquine
(0.25 mg base/kg) can be safely administered even without
prior G6PD testing [1]. Once evidence accumulates that
this strategy can indeed safely block the transmission of
P. falciparum the focus of G6PD tests will be the detec-
tion of individuals at risk for haemolysis following 8-
aminoquinoline therapy targeting hypnozoites.
These strategies target a critically important global
health problem: the inability to safely treat a potentially
life-threatening infection. The consequences of morbid-
ity and opportunities for the transmission caused by the
relapses of vivax malaria have been operationally and
scientifically neglected. A better understanding of the
risk benefit ratio of deploying or withholding prima-
quine regimens is crucial for the wider use of 8-
aminoquinolines. The Asian nations carrying the bulk
of the global P. vivax burden now look to the scientific
community to finally solve the 60-year-old primaquine
toxicity problem and provide a more effective chemo-
therapeutic management of the many species, stages,
and clinical manifestations known collectively as the
endemic malarias [73,74].
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7. Investigation of the mean level of haemolysis in uncomplicated malaria without primaquine treatment.
8. What are acceptable test characteristics (e g, sensitivity and specificity) of rapid tests in various populations and field conditions?
9. High resolution mapping of G6PD deficiency and haemolysis risks across major malaria endemic settings.
10. Analysis of the cost-effectiveness of G6PD deficiency tests and the risk benefit of deploying or withholding primaquine regimens for P. vivax
infections.
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